Bacteriophage Therapy Market: Distribution by Therapeutic Area (Infectious Diseases, Oncological Disorders, and Other Disorders), Route of Administration (Oral, Topical, Rectal and Intravenous), and Geography (North America, Europe, Asia-Pacific, and Rest of the World): Industry Trends and Global Forecasts, 2022-2035

  • Lowest Price Guaranteed From USD 5,899

  • Published
    October 2022

  • Pages
    220

  • View Count
    288

Example Insights

Bacteriophage-Therapeutics-Market-Context-thumb Bacteriophage-Therapeutics-Market-Bacteriophage-Therapeutics-thumb Bacteriophage-Therapeutics-Market-Status-of-Development-thumb Bacteriophage-Therapeutics-Market-Geographical-Distribution-thumb
Bacteriophage-Therapeutics-Market-Patent-Analysis-thumb Bacteriophage-Therapeutics-Market-Publication-Analysis-thumb Bacteriophage-Therapeutics-Market-Grant-Analysis-thumb Bacteriophage-Therapeutics-Market-Funding-and-Investments-thumb
Bacteriophage-Therapeutics-Market-Collaborations-thumb Bacteriophage-Therapeutics-Market-Health-Indexing-thumb Bacteriophage-Therapeutics-Market-Therapeutics-Market-thumb  

Overview

Antimicrobial resistance (AMR) has been identified as one of the greatest threats to public health. According to the Centers of Disease Control and Prevention, more than 2.8 million cases of AMR infections are identified in the United States on an annual basis, leading to death of more than 35,000 people. Further, World Health Organization (WHO) has estimated that, by 2050, the increasing burden of such infections is expected to increase the healthcare expenditure by USD 1.2 trillion, annually. To address this situation, WHO has developed a global action plan for raising public awareness, reducing the incidence of infections, and optimizing the use of antimicrobial drugs, paving the way for the development of alternative anti-infectious modalities. One such example of these modalities includes bacteriophage therapies. These therapeutics have been used in healthcare for over a century, providing an alternative approach to target the disease-causing multi-drug resistant bacteria; however, their use has been limited. With the growing need for therapies targeting AMR infections, bacteriophage therapy are now gaining more traction. These therapeutics tend to cause minimal drug toxicity, replicate themselves at the site of action, have reduced side-effects, and have the potential to self-decompose when the infection causing bacteria have been exterminated.

Given the afore-mentioned advantages of bacteriophage therapy and promising insights from the ongoing research, various clinical trials have been registered for the clinical evaluation of bacteriophage therapies. In fact, with the widespread participation of stakeholders in the research and development of bacteriophage therapy, clinical studies evaluating bacteriophage therapy have increased at a growth rate of more than 30% over the last few years. Moreover, the volume of affiliated scientific literature (2,200+ related publications since 2018) has also increased, demonstrating the growing popularity of bacteriophage therapy and related technologies. Given the encouraging results, this domain has piqued the interest of many private and public investors who have invested more than USD 1 billion over the last few years. With increasing R&D efforts, promising clinical data, and financial support from investors, we anticipate the bacteriophage therapy market to witness notable growth in the mid to long term.

Scope of the Report

The “bacteriophage therapy Market - Distribution by Therapeutic Area (Infectious Diseases, Oncological Disorders, and Other Disorders), Route of Administration (Oral, Topical, Rectal and Intravenous), and Geography (North America, Europe and Asia-Pacific): Industry Trends and Global Forecasts, 2022-2035” report features an extensive study on the current market landscape, offering an informed opinion on the likely evolution and future opportunities associated with the bacteriophage therapy market. The study underlines an in-depth analysis, highlighting the key drivers and the market trends related to this evolving segment of the pharmaceutical industry. Amongst other elements, the report includes:

  • A summary of the key insights from the bacteriophage therapy market. It offers a high-level view on the current state of the market and its likely evolution in the mid to long term.
  • A general overview of the historical evolution of bacteriophages and their biology. It also includes a detailed discussion on applications of bacteriophage therapy. The chapter concludes with a discussion on the various advantages and limitations associated with the bacteriophage therapy.
  • A detailed overview of the overall market landscape of bacteriophage therapy, including information on their current status of development (marketed, clinical, preclinical and discovery), key therapeutic areas (infectious diseases, oncological disorders, and other disorders), type of bacterial strain (Pseudomonas aeruginosa, Escherichia coli, Staphylococcus aureus, Klebsiella pneumoniae, Salmonella, Streptococcus, Acinetobacter baumannii and others), target disease indication (lung infection, bone infection, urinary tract infection, gastrointestinal infection, bacterial infection, blood infection, other disorders, and multiple infections), type of therapy (monotherapy, combination therapy, and both), route of administration (oral route, topical route, rectal route and intravenous route), and information on bacteriophage related technologies.
  • An overview of the current status of the market with respect to the players engaged in the manufacturing of bacteriophage therapy, featuring information on the year of establishment, company size, location of headquarters, and leading developers.
  • Elaborate profiles of the prominent players engaged in the development of bacteriophage therapy (shortlisted based on the number of drugs progressed to advanced phases of development). Each profile features a brief overview of the company, its financial information (if available), details on its product portfolio, and a section on recent developments and an informed future outlook.
  • An in-depth analysis of completed, ongoing and planned clinical studies, based on several relevant parameters, such as trial registration year, trial phase, enrolled patient population, study design, type of sponsor / collaborator, most active players (in terms of number of registered trials), registered trials, and geographical region (by number of registered trials and number of enrolled patient population).
  • An in-depth analysis of the various patents that have been filed / granted related to bacteriophage therapy. It includes information on key parameters, such as type of patent (granted patents, patent applications and others), publication year, application year, number of granted patents and patent applications, geographical distribution, Cooperative Patent Classification (CPC) symbols, and type of applicant. It also highlights the leading industry and non-industry players and individual assignees (in terms of number of patents filed / granted). 
  • An in-depth analysis of various publications for bacteriophage therapy, based on several relevant parameters, such as year of publication, type of article, popular keywords, most popular publishers (in terms of number of publications), key journals (in terms of number of articles published and journal impact factor). It also highlights benchmarking of the publications to develop more insightful opinions on the recent trends related to research and development in this area.   
  • A detailed study of the various grants that have been awarded to research institutes engaged in projects related to bacteriophage therapy, since 2017, highlighting various important parameters, such as year of award, amount awarded, funding institute, support period, grant type, purpose of grant, focus area, type of recipient organization, and leading recipient organizations.
  • An in-depth analysis of the investments made, including grants, venture capital financing, initial public offering, secondary offering, private placement, equity and debt funding, at various stages of development, in companies that are focused on developing bacteriophage therapy.
  • A detailed study of the recent collaborations and partnership established in this domain since 2017, including the details of deals that were / are focused on the development of bacteriophage therapy, which were analyzed based on several parameters such as year of partnership, type of partnership (research and development agreement, product development agreement, licensing agreement, merger / acquisition, commercialization agreement, manufacturing agreement, clinical trial agreement, supply agreement, distribution agreement and other agreement), therapeutic area (infectious diseases, hepatological disorders, chronic inflammatory disorders, skin disorders and women’s health), application areas (human health, animal health, diagnostic test, aquaculture, food safety, food safety and environment protection and livestock farming), and regional distribution of partnerships. 
  • An analysis of the various start-ups engaged in the development of bacteriophage therapy, based on relevant parameters, such as pipeline strength, pipeline maturity, indication diversity, number of patents, financial support and partnership activity

One of the key objectives of the report was to estimate the current market size and potential growth opportunities, over the coming 13 years. Based on various parameters, such as target patient population, region specific adoption rates, and the likely selling price of such therapeutic products, we have provided informed estimates on the evolution of the market in the short to mid-term and long term, for the period 2022-2035. In order to evaluate the current and future opportunity associated with the bacteriophage therapy market, our year-wise projections have been segmented based on several relevant parameters such as, target therapeutic area (infectious diseases, oncological disorders, and other disorders), route of administration (oral, topical, rectal and intravenous), and geographical region (North America, Europe, Asia Pacific, and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the market’s evolution.

The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:

  • Antoine Culot (Chief Executive Officer, Rime Bioinformatics)
  • Iddo Weiner (Senior Director, Head of Data-Science, BiomX)
  • Mathieu Medina (Project Leader, Hospices Civils De Lyon)
  • Mohammadreza Azizkhani (Independent Consultant) 

All actual figures have been sourced and analysed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the leading players engaged in the development of bacteriophage therapy?
  • What are the various bacteriophage therapy candidates in the current development pipeline? 
  • Which geographies are the most active in conducting clinical trials related to bacteriophage therapy?
  • What is the focus area of various publications related to bacteriophage therapy?
  • Which partnership models are commonly adopted by industry and non-industry stakeholders?
  • What are the different initiatives undertaken by start-ups for the development of bacteriophage therapy in the recent past?
  • How is the current and future market opportunity, likely to be distributed across key market segments?

Contents

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Market Segmentations
1.3. Research Methodology
1.4. Key Questions Answered
1.5. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Historical Evolution of Bacteriophages
3.3. Biology of Bacteriophages
3.4. Introduction to Bacteriophage Therapy
3.5. Applications of Bacteriophage Therapy
3.6. Advantages of Bacteriophage Therapy
3.7. Limitations of Bacteriophage Therapy
3.8. Conclusion

4. bacteriophage therapy: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. bacteriophage therapy: Drug Pipeline
4.2.1. Analysis by Phase of Development
4.2.2. Analysis by Therapeutic Area
4.2.3. Analysis by Phase of Development and Therapeutic Area
4.2.4. Analysis by Targeted Bacterial Strain
4.2.5. Analysis by Target Disease Indication
4.2.6. Analysis by Type of Therapy
4.2.7. Analysis by Route of Administration

4.3. Information on Bacteriophage Related Technologies

5. bacteriophage therapy: DEVELOPER LANDSCAPE
5.1. Chapter Overview
5.2. bacteriophage therapy: List of Developers
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters
5.2.4. Analysis by Company Size and Location of Headquarters
5.2.5. Leading Developers: Analysis by Number of bacteriophage therapy

6. COMPANY AND DRUG PROFILES
6.1. Chapter Overview
6.2. Eliava BioPreparations
6.2.1. Company Overview
6.2.2. Financial Information
6.2.3. Pipeline Overview
6.2.3.1. Pyo Bacteriophage
6.2.3.2. Intesti Bacteriophage
6.2.3.3. SES Bacteriophage
6.2.3.4. Staphylococcal Bacteriophage
6.2.3.5. Fersisi Bacteriophage
6.2.3.6. Enko Bacteriophage
6.2.4. Recent Developments and Future Outlook

6.3. Micreos
6.3.1. Company Overview
6.3.2. Financial Information
6.3.3. Pipeline Overview
6.3.3.1. PhageGuard Listex
6.3.3.2. PhageGuard S
6.3.3.3. PhageGuard E
6.3.4. Recent Developments and Future Outlook

6.4. NPO Microgen
6.4.1. Company Overview
6.4.2. Financial Information
6.4.3. Pipeline Overview
6.4.3.1. E. coli-Proteus Bacteriophage
6.4.3.2. Streptococcus Bacteriophage
6.4.3.3. Complex Pyobacteriophage
6.4.3.4. Klebsiella Purified Polyvalent Bacteriophage
6.4.3.5. Sextaphag
6.4.3.6. Dysentery Bacteriophage
6.4.3.7. Intesti
6.4.4. Recent Developments and Future Outlook

6.5. ContraFect
6.5.1. Company Overview
6.5.2. Financial Information
6.5.3. Pipeline Overview
6.5.3.1. Exebacase (CF-301)
6.5.3.2. CF-296
6.5.3.3. CF-370
6.5.3.4. Gram-Negative Lysins
6.5.3.5. Amurins
6.5.4. Recent Developments and Future Outlook

6.6. Adaptive Phage Therapeutics
6.6.1. Company Overview
6.6.2. Financial Information
6.6.3. Pipeline Overview
6.6.3.1. bacteriophage therapy
6.6.4. Recent Developments and Future Outlook

6.7. Phagelux
6.7.1. Company Overview
6.7.2. Financial Information
6.7.3. Pipeline Overview
6.7.3.1. PGX-0100
6.7.3.2. BactelideTM
6.7.3.3. BactelideTM
6.7.4. Recent Developments and Future Outlook

6.8. Pherecydes Pharma
6.8.1. Company Overview
6.8.2. Financial Information
6.8.3. Pipeline Overview
6.8.3.1. bacteriophage therapy
6.8.4. Recent Developments and Future Outlook

7. CLINICAL TRIAL ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology

7.3. bacteriophage therapy Market: Clinical Trial Analysis
7.3.1. Analysis by Trial Registration Year
7.3.2. Analysis by Trial Registration Year and Enrolled Patient Population
7.3.3. Analysis by Trial Status
7.3.4. Analysis by Trial Phase and Enrolled Patient Population
7.3.5. Analysis by Study Design
7.3.6. Analysis by Type of Sponsor / Collaborator
7.3.7. Most Active Players: Analysis by Number of Registered Trials

7.3.8. Regional Analysis
7.3.8.1. Analysis by Number of Registered Trials
7.3.8.2. Analysis by Enrolled Patient Population

8. PATENT ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology

8.3. bacteriophage therapy: Patent Analysis
8.3.1. Analysis by Publication Year
8.3.2. Analysis by Patent Application Year
8.3.3. Analysis by Annual Number of Granted Patent(s) and Patent Application(s)
8.3.4. Analysis by Geography
8.3.5. Analysis by CPC Symbols
8.3.6. Analysis by Type of Applicant
8.3.7. Leading Players: Analysis by Number of Patents

8.4. bacteriophage therapy: Patent Benchmarking
8.4.1. Analysis by Patent Characteristics

8.5. bacteriophage therapy: Patent Valuation
8.6. List of Leading Patents

9. PUBLICATION BENCHMARKING ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology

9.2.1. Analysis by Year of Publication
9.2.2. Analysis by Type of Article
9.2.3. Analysis by Popular Keywords
9.2.4. Popular Publishers: Analysis by Number of Publications
9.2.5. Popular Journals: Analysis by Number of Publications
9.2.6. Popular Journals: Analysis by Journal Impact Factor
9.2.7. Publications: Timeline Analysi
9.3. Publication Benchmarking

10. ACADEMIC GRANTS ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology

10.3. bacteriophage therapy: Academic Grant Analysis
10.3.1. Analysis by Year of Grant Award
10.3.2. Analysis by Amount Awarded
10.3.3. Analysis by Administering Institute Center
10.3.4. Analysis by Support Period
10.3.5. Analysis by Funding Institute Center and Support Period
10.3.6. Analysis by Type of Grant Application
10.3.7. Analysis by Purpose of Grant Award
10.3.8. Analysis by Activity Code
10.3.9. Word Cloud Analysis: Emerging Focus Areas
10.3.10. Analysis by Study Section Involved
10.3.11. Popular NIH Departments: Analysis by Number of Grants
10.3.12. Analysis by Type of Recipient Organization
10.3.13. Prominent Program Officers: Analysis by Number of Grants
10.3.14. Popular Recipient Organizations: Analysis by Number of Grants
10.3.15. Regional Distribution of Recipient Organizations

11. FUNDING AND INVESTMENT ANALYSIS
11.1. Chapter Overview
11.2. Types of Funding
11.3. bacteriophage therapy Market: List of Funding and Investments
11.3.1. Analysis by Year of Investment
11.3.2. Analysis by Amount Invested
11.3.3. Analysis by Type of Funding
11.3.4. Most Active Players: Analysis by Number of Funding Rounds and Amount Raised
11.3.5. Investors Analysis
11.3.6. Regional Distribution by Amount Invested

11.4. Concluding Remarks

12. PARTNERSHIPS AND COLLABORATIONS
12.1. Chapter Overview
12.2. Partnership Models
12.3. bacteriophage therapy: List of Partnerships and Collaborations
12.3.1. Analysis by Year of Partnership
12.3.2. Analysis by Type of Partnership
12.3.3. Analysis by Year of Partnership and Type of Partner
12.3.4. Analysis by Therapeutic Area
12.3.5. Analysis by Application Area
12.3.6. Most Active Players: Analysis by Number of Partnerships

12.3.7. Regional Analysis
12.3.7.1. Intercontinental and Intracontinental Agreements

13. START-UP HEALTH INDEXING
13.1. Chapter Overview
13.2. bacteriophage therapy Developers: Start-ups
13.2.1. Analysis by Location of Headquarters

13.3. Benchmarking of Start-ups
13.3.1. Analysis by Pipeline Strength
13.3.2. Analysis by Pipeline Maturity
13.3.3. Analysis by Indication Diversity
13.3.4. Analysis by Number of Patents
13.3.5. Analysis by Funding Amount
13.3.6. Analysis by Partnership Activity
13.3.7. Start-ups Health Indexing: Roots Analysis Perspective

14. MARKET FORECAST AND OPPORTUNITY ANALYSIS
14.1. Chapter Overview
14.2. Scope and Assumptions
14.3. Forecast Methodology

14.4. Global bacteriophage therapy Market, 2022-2035
14.4. 1. bacteriophage therapy Market, 2022-2035: Distribution by Therapeutic Area
14.4.1.1. bacteriophage therapy Market for Gastrointestinal Infectious, 2022-2035
14.4.1.2. bacteriophage therapy Market for Bacterial Dysentery, 2022-2035
14.4.1.3. bacteriophage therapy Market for Multiple Infections, 2022-2035

14.4. 2. bacteriophage therapy Market, 2022-2035: Distribution by Route of Administration
14.5.2.1. bacteriophage therapy Market for Oral Therapies, 2022-2035
14.5.2.2. bacteriophage therapy Market for Rectal Therapies, 2022-2035
14.5.2.3. bacteriophage therapy Market for Intravesical Therapies, 2022-2035
14.5.2.4. bacteriophage therapy Market for Topical Therapies, 2022-2035

14.4. 3. bacteriophage therapy Market, 2022-2035: Distribution by Geography
14.6.3.1. bacteriophage therapy in North America, 2022-2035
14.6.3.2. bacteriophage therapy in Europe, 2022-2035

15. CONCLUSION

16. EXECUTIVE INSIGHTS
16.1. Chapter Overview
16.2. Rime Bioinformatics
16.2.1. Company Snapshot
16.2.2. Interview Transcript: Antoine Culot, Chief Executive Officer

16.3. BiomX
16.3.1. Company Snapshot
16.3.2. Interview Transcript: Iddo Weiner, Senior Director, Head of Data-Science

16.4. Hospices Civils De Lyon
16.4.1. Organization Snapshot
16.4.2. Interview Transcript: Mathieu Medina, Project Leader

16.5. Independent Consultant
16.5.1. Interview Transcript: Mohammadreza Azizkhani, Scientific Researcher

17. APPENDIX I: TABULATED DATA

18. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 History Timeline of Bacteriophage
Figure 3.2 Bacteriophage Replication Cycle
Figure 3.3 Advantages of Bacteriophage Therapy
Figure 3.4 Limitations of Bacteriophage Therapy
Figure 4.1 bacteriophage therapy: Distribution by Phase of Development
Figure 4.2 bacteriophage therapy: Distribution by Therapeutic Area
Figure 4.3 bacteriophage therapy: Distribution by Phase of Development and Therapeutic Area
Figure 4.4 bacteriophage therapy: Distribution by Targeted Bacterial Strain
Figure 4.5 bacteriophage therapy: Distribution by Target Disease Indication
Figure 4.6 bacteriophage therapy: Distribution by Type of Therapy
Figure 4.7 bacteriophage therapy: Distribution by Route of Administration
Figure 5.1 bacteriophage therapy Developers: Distribution by Year of Establishment
Figure 5.2 bacteriophage therapy Developers: Distribution by Company Size
Figure 5.3 bacteriophage therapy Developers: Distribution by Location of Headquarters
Figure 5.4 bacteriophage therapy Developers: Distribution by Company Size and Location of Headquarters
Figure 5.5 Leading Developers: Distribution by Number of bacteriophage therapy
Figure 7.1 Clinical Trial Analysis: Scope and Methodology
Figure 7.2 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2010-2022
Figure 7.3 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, 2010-2022
Figure 7.4 Clinical Trial Analysis: Distribution by Trial Status
Figure 7.5 Clinical Trial Analysis: Cumulative Year-wise Trend by Trial Status
Figure 7.6 Clinical Trial Analysis: Distribution by Trial Phase and Enrolled Patient Population
Figure 7.7 Clinical Trial Analysis: Distribution by Study Design
Figure 7.8 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 7.10 Most Active Players: Distribution by Number of Registered Trials
Figure 7.11 Geographical Analysis: Distribution by Number of Registered Trials
Figure 7.12 Geographical Analysis: Distribution by Enrolled Patient Population
Figure 8.1 Patent Analysis: Distribution by Type of Patent
Figure 8.2 Patent Analysis: Cumulative Distribution by Publication Year, Till 2022
Figure 8.3 Patent Analysis: Cumulative Distribution by Patent Application Year, Till 2022
Figure 8.4 Patent Analysis: Year-wise Distribution by Annual Number of Granted Patent(s) and Patent Application(s), Till 2022
Figure 8.5 Patent Analysis: Distribution by Geography
Figure 8.6 Patent Analysis: Distribution by CPC Symbols
Figure 8.7 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant, Till 2022
Figure 8.8 Leading Industry Players: Distribution by Number of Patents
Figure 8.9 Leading Non-Industry Players: Distribution by Number of Patents
Figure 8.10 Leading Industry Players: Benchmarking by Patent Characteristics (CPC Symbols)
Figure 8.11 Patent Analysis: Distribution by Patent Age
Figure 8.12 Patent Valuation Analysis
Figure 9.1 Publication Benchmarking Analysis: Cumulative Year-wise Trend, 2018-2022
Figure 9.2 Publication Benchmarking Analysis: Distribution by Type of Article
Figure 9.3 Publication Benchmarking Analysis: Distribution by Popular Keywords
Figure 9.4 Popular Publishers: Distribution by Number of Publications
Figure 9.5 Popular Journals: Distribution by Number of Publications
Figure 9.6 Popular Journals: Distribution by Journal Impact Factor
Figure 9.7 Timeline Analysis: Distribution by Article Type and Average Time to Publish
Figure 9.8 Timeline Analysis: Distribution by Journal Impact Factor and Average Time to Publish
Figure 9.9 Timeline Analysis: Distribution by Type of Article and Maximum Time to Publish
Figure 9.10 Timeline Analysis: Distribution by Journal Impact Factor and Maximum Time to Publish
Figure 9.11 Publication Benchmarking
Figure 10.1 Grant Analysis: Cumulative Year-wise Distribution of Grants Awarded, 2017-2022
Figure 10.2 Grant Analysis: Cumulative Year-wise Distribution by Amount Awarded (USD Million), 2017-2022
Figure 10.3 Grant Analysis: Distribution by Administering Institute Center
Figure 10.4 Grant Analysis: Distribution by Support Period
Figure 10.5 Grant Analysis: Distribution by Funding Institute Center and Support Period
Figure 10.6 Grant Analysis: Distribution by Type of Grant Application
Figure 10.7 Grant Analysis: Distribution by Purpose of Grant Award
Figure 10.8 Grant Analysis: Distribution by Activity Code
Figure 10.9 Word Cloud: Emerging Focus Areas
Figure 10.10 Grant Analysis: Distribution by Study Section Involved
Figure 10.11 Popular NIH Departments: Distribution by Number of Grants
Figure 10.12 Grant Analysis: Distribution by Types of Recipient Organization
Figure 10.13 Most Prominent Program Officers: Distribution by Number of Grants
Figure 10.14 Popular Recipient Organization: Distribution by Number of Grants
Figure 10.15 Grant Analysis: Regional Distribution of Recipient Organization
Figure 11.1 Funding and Investment Analysis: Cumulative Year-wise Trend, 2017-2022
Figure 11.2 Funding and Investment Analysis: Cumulative Amount Invested (USD Million), 2017-2022
Figure 11.3 Funding and Investment Analysis: Distribution of Instances by Type of Funding, 2017-2022
Figure 11.4 Funding and Investment Analysis: Distribution of the Total Amount Invested (USD Million) by Type of Funding, 2017-2022
Figure 11.5 Most Active Players: Distribution by Number of Funding Rounds and Amount Raised
Figure 11.6 Most Active Investors: Distribution by Number of Instances
Figure 11.7 Funding and Investment Analysis: Regional Distribution of Total Amount Invested, 2017-2022
Figure 12.1 Partnerships and Collaborations: Cumulative Year-Wise Trend, 2017-2022
Figure 12.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 12.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2017-2022
Figure 12.4 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner, 2017-2022
Figure 12.5 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 12.6 Partnerships and Collaborations: Distribution by Application Area
Figure 12.7 Most Active Players: Distribution by Number of Partnerships
Figure 12.8 Partnerships and Collaborations: Regional Distribution
Figure 12.9 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 13.1 Startup-Health Indexing: Distribution by Location of Headquarters
Figure 13.2 Startup-Health Indexing: Distribution by Pipeline Strength
Figure 13.3 Startup-Health Indexing: Distribution by Pipeline Maturity
Figure 13.4 Startup-Health Indexing: Distribution by Indication Diversity
Figure 13.5 Startup-Health Indexing: Distribution by Number of Patents
Figure 13.6 Startup-Health Indexing: Distribution by Funding Amount
Figure 13.7 Start-up Health Indexing: Roots Analysis Perspective
Figure 13.8 Start-up Health Indexing: Leading Companies
Figure 14.1 Global bacteriophage therapy Market, 2022-2035 (USD Million)
Figure 14.2 Global bacteriophage therapy Market for Therapeutic Area, 2022-2035 (USD Million)
Figure 14.3 bacteriophage therapy Market for Gastrointestinal Infectious, 2022-2035 (USD Million)
Figure 14.4 bacteriophage therapy Market for Bacterial Dysentery, 2022-2035 (USD Million) 2022-2035 (USD Million)
Figure 14.5 bacteriophage therapy Market for Multiple Infections, 2022-2035 (USD Million)
Figure 14.6 bacteriophage therapy Market for Other Infections, 2022-2035 (USD Million)
Figure 14.7 Global bacteriophage therapy Market for Route of Administration, 2022-2035 (USD Million)
Figure 14.8 bacteriophage therapy Market for Oral Therapies, 2022-2035 (USD Million)
Figure 14.9 bacteriophage therapy Market for Rectal Therapies, 2022-2035 (USD Million)
Figure 14.10 bacteriophage therapy Market for Intravesical Therapies, 2022-2035 (USD Million)
Figure 14.11 Global bacteriophage therapy Market for Regional Distribution, 2022-2035 (USD Million)
Figure 14.12 bacteriophage therapy Market in North America, 2022-2035 (USD Million)
Figure 14.13 bacteriophage therapy Market in North America, 2022-2035 (USD Million)
Figure 14.14 bacteriophage therapy Market in Europe, 2022-2035 (USD Million)
Figure 14.15 Complex Pyobacteriophage: Sales Forecast till 2035 (USD Million)
Figure 14.16 Dysentery Bacteriophage: Sales Forecast till 2035 (USD Million)
Figure 14.17 E.coli-Proteus Bacteriophage: Sales Forecast till 2035 (USD Million)
Figure 14.18 Enko BACTERIOPHAGE: Sales Forecast till 2035 (USD Million)
Figure 14.19 Fersisi BACTERIOPHAGE: Sales Forecast till 2035 (USD Million)
Figure 14.20 Intesti: Sales Forecast till 2035 (USD Million)
Figure 14.21 Intesti Bacteriophage: Sales Forecast till 2035 (USD Million)
Figure 14.22 Klebsiella Purified Polyvalent Bacteriophage: Sales Forecast till 2035 (USD Million)
Figure 14.23 Pyo Bacteriophage: Sales Forecast till 2035 (USD Million)
Figure 14.24 SES Bacteriophage: Sales Forecast till 2035 (USD Million)
Figure 14.25 Sextaphag®: Sales Forecast till 2035 (USD Million)
Figure 14.26 Staphylococcal Bacteriophage: Sales Forecast till 2035 (USD Million)
Figure 14.27 Streptococcus Bacteriophage: Sales Forecast till 2035 (USD Million)
Figure 14.28 Pyo Bacteriophage: Sales Forecast till 2035 (USD Million)
Figure 14.29 PYO Phage Streptococcus Bacteriophage: Sales Forecast till 2035 (USD Million)
Figure 14.30 Unnamed Streptococcus Bacteriophage (Adaptive Phage Therapeutics): Sales Forecast till 2035 (USD Million)
Figure 15.1 Concluding Remarks: Market Landscape
Figure 15.2 Concluding Remarks: Clinical Trial Analysis
Figure 15.3 Concluding Remarks: Patent Analysis
Figure 15.4 Concluding Remarks: Publication Benchmarking Analysis
Figure 15.5 Concluding Remarks: Academic Grants Analysis
Figure 15.6 Concluding Remarks: Funding and Investment Analysis
Figure 15.7 Concluding Remarks: Partnerships and Collaborations
Figure 15.8 Concluding Remarks: Start-up Health Indexing
Figure 15.9 Concluding Remarks: Market Sizing and Opportunity Analysis

List Of Tables

Table 4.1 bacteriophage therapy: Information on Developer, Phase of Development, Bacterial Target, Target Disease Indication, Therapeutic Area
Table 4.2 bacteriophage therapy: Information on Type of Therapy and Route of Administration
Table 4.2 bacteriophage therapy: Information on Bacteriophage Related Technologies
Table 5.1 bacteriophage therapy: List of Developers
Table 6.1 Eliava BioPreparations: Company Overview
Table 6.2 Eliava BioPreparations: Pipeline Overview
Table 6.3 Micreos: Company Overview
Table 6.4 Micreos: Pipeline Overview
Table 6.5 NPO Microgen: Company Overview
Table 6.6 NPO Microgen: Pipeline Overview
Table 6.7 ContraFect: Company Overview
Table 6.8 ContraFect: Pipeline Overview
Table 6.9 Adaptive Phage Therapeutics: Company Overview
Table 6.10 Adaptive Phage Therapeutics: Pipeline Overview
Table 6.11 Phagelux: Company Overview
Table 6.12 Phagelux: Pipeline Overview
Table 6.13 Pherecydes Pharma: Company Overview
Table 6.4 Pherecydes Pharma: Pipeline Overview
Table 8.1 List of Top CPC Sections
Table 8.2 List of Top CPC Symbols
Table 8.3 List of Top CPC Codes
Table 8.4 Patent Analysis: Summary of Benchmarking
Table 8.5 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 8.6 Patent Portfolio: List of Leading Patents (by Number of Citations)
Table 9.1 Publication Benchmarking: List of Top 50 Publications
Table 11.1 bacteriophage therapy: List of Funding and Investments, 2017-2022
Table 11.2 Funding and Investment Analysis: Summary of Investment
Table 12.1 bacteriophage therapy: List of Partnerships and Collaborations, 2017-2022
Table 17.1 bacteriophage therapy: Distribution by Phase of Development
Table 17.2 bacteriophage therapy: Distribution by Therapeutic Area
Table 17.3 bacteriophage therapy: Distribution by Phase of Development and Therapeutic Area
Table 17.4 bacteriophage therapy: Distribution by Targeted Bacterial Strain
Table 17.5 bacteriophage therapy: Distribution by Target Disease Indication
Table 17.6 bacteriophage therapy: Distribution by Type of Therapy
Table 17.7 bacteriophage therapy: Distribution by Route of Administration
Table 17.8 bacteriophage therapy Developers: Distribution by Year of Establishment
Table 17.9 bacteriophage therapy Developers: Distribution by Company Size
Table 17.10 bacteriophage therapy Developers: Distribution by Location of Headquarters
Table 17.11 bacteriophage therapy Developers: Distribution by Company Size and Location of Headquarters
Table 17.12 Leading Developers: Distribution by Number of bacteriophage therapy
Table 17.13 Clinical Trial Analysis: Scope and Methodology
Table 17.14 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2010-2022
Table 17.15 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, 2010-2022
Table 17.16 Clinical Trial Analysis: Distribution by Trial Status
Table 17.17 Clinical Trial Analysis: Cumulative Year-wise Trend by Trial Status
Table 17.18 Clinical Trial Analysis: Distribution by Trial Phase and Enrolled Patient Population
Table 17.19 Clinical Trial Analysis: Distribution by Study Design
Table 17.20 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 17.21 Most Active Players: Distribution by Number of Registered Trials
Table 17.22 Geographical Analysis: Distribution by Number of Registered Trials
Table 17.23 Geographical Analysis: Distribution by Enrolled Patient Population
Table 17.24 Patent Analysis: Distribution by Type of Patent
Table 17.25 Patent Analysis: Cumulative Distribution by Publication Year, Till 2022
Table 17.26 Patent Analysis: Cumulative Distribution by Patent Application Year, Till 2022
Table 17.27 Patent Analysis: Year-wise Distribution by Annual Number of Granted Patent(s) and Patent Application(s), Till 2022
Table 17.28 Patent Analysis: Distribution by Geography
Table 17.29 Patent Analysis: Distribution by CPC Symbols
Table 17.30 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant, Till 2022
Table 17.31 Leading Industry Players: Distribution by Number of Patents
Table 17.32 Leading Non-Industry Players: Distribution by Number of Patents
Table 17.33 Leading Industry Players: Benchmarking by Patent Characteristics (CPC Symbols)
Table 17.34 Patent Analysis: Distribution by Patent Age
Table 17.35 Patent Valuation Analysis
Table 17.36 Publication Benchmarking Analysis: Cumulative Year-wise Trend, 2018-2022
Table 17.37 Publication Benchmarking Analysis: Distribution by Type of Article
Table 17.38 Publication Benchmarking Analysis: Distribution by Popular Keywords
Table 17.39 Popular Publishers: Distribution by Number of Publications
Table 17.40 Popular Journals: Distribution by Number of Publications
Table 17.41 Popular Journals: Distribution by Journal Impact Factor
Table 17.42 Grant Analysis: Cumulative Year-wise Distribution of Grants Awarded, 2017-2022
Table 17.43 Grant Analysis: Cumulative Year-wise Distribution by Amount Awarded (USD Million), 2017-2022
Table 17.44 Grant Analysis: Distribution by Administering Institute Center
Table 17.45 Grant Analysis: Distribution by Support Period
Table 17.46 Grant Analysis: Distribution by Funding Institute Center and Support Period
Table 17.47 Grant Analysis: Distribution by Type of Grant Application
Table 17.49 Grant Analysis: Distribution by Purpose of Grant Award
Table 17.49 Grant Analysis: Distribution by Activity Code
Table 17.50 Grant Analysis: Distribution by Study Section Involved
Table 17.51 Popular NIH Departments: Distribution by Number of Grants
Table 17.52 Grant Analysis: Distribution by Types of Recipient Organization
Table 17.53 Most Prominent Program Officers: Distribution by Number of Grants
Table 17.54 Popular Recipient Organization: Distribution by Number of Grants
Table 17.55 Grant Analysis: Regional Distribution of Recipient Organization
Table 17.56 Funding and Investment Analysis: Cumulative Year-wise Trend, 2017-2022
Table 17.57 Funding and Investment Analysis: Cumulative Amount Invested (USD Million), 2017-2022
Table 17.58 Funding and Investment Analysis: Distribution of Instances by Type of Funding, 2017-2022
Table 17.59 Funding and Investment Analysis: Distribution of the Total Amount Invested (USD Million) by Type of Funding, 2017-2022
Table 17.60 Most Active Players: Distribution by Number of Funding Rounds and Amount Raised
Table 17.61 Most Active Investors: Distribution by Number of Instances
Table 17.62 Funding and Investment Analysis: Regional Distribution of Total Amount Invested, 2017-2022
Table 17.63 Partnerships and Collaborations: Cumulative Year-Wise Trend, 2017-2022
Table 17.64 Partnerships and Collaborations: Distribution by Type of Partnership
Table 17.65 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2017-2022
Table 17.66 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner, 2017-2022
Table 17.67 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 17.68 Partnerships and Collaborations: Distribution by Application Area
Table 17.69 Most Active Players: Distribution by Number of Partnerships
Table 17.70 Partnerships and Collaborations: Regional Distribution
Table 17.71 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 17.72 Startup-Health Indexing: Distribution by Location of Headquarters
Table 17.73 Startup-Health Indexing: Distribution by Pipeline Strength
Table 17.74 Startup-Health Indexing: Distribution by Pipeline Maturity
Table 17.75 Startup-Health Indexing: Distribution by Indication Diversity
Table 17. 76 Startup-Health Indexing: Distribution by Number of Patents
Table 17.77 Startup-Health Indexing: Distribution by Funding Amount
Table 17.78 Start-up Health Indexing: Roots Analysis Perspective
Table 17.79 Start-up Health Indexing: Leading Companies
Table 17.80 Global bacteriophage therapy Market, 2022-2035 (USD Million)
Table 17.81 bacteriophage therapy Market for Market for Infectious Diseases, 2022-2035 (USD Million)
Table 17.82 bacteriophage therapy Market for Oncological Diseases, 2022-2035 (USD Million) 2022-2035 (USD Million)
Table 17.83 bacteriophage therapy Market for Other Disorders, 2022-2035 (USD Million)
Table 17.84 bacteriophage therapy Market for Oral Therapies, 2022-2035 (USD Million)
Table 17.85 bacteriophage therapy Market for Topical Therapies, 2022-2035 (USD Million)
Table 17.86 bacteriophage therapy Market for Rectal Therapies, 2022-2035 (USD Million)
Table 17.87 bacteriophage therapy Market for Intravenous Therapies, 2022-2035 (USD Million)
Table 17.88 bacteriophage therapy Market in North America, 2022-2035 (USD Million)
Table 17.89 bacteriophage therapy Market in Europe, 2022-2035 (USD Million)
Table 17.90 bacteriophage therapy Market in Asia Pacific, 2022-2035 (USD Million)
Table 17.91 bacteriophage therapy Market in Rest of the World, 2022-2035 (USD Million)
Table 17.92 Complex Pyobacteriophage: Sales Forecast till 2035 (USD Million)
Table 17.93 Dysentery Bacteriophage: Sales Forecast till 2035 (USD Million)
Table 17.94 E.coli-Proteus Bacteriophage: Sales Forecast till 2035 (USD Million)
Table 17.95 Enko BACTERIOPHAGE: Sales Forecast till 2035 (USD Million)
Table 17.96 Fersisi BACTERIOPHAGE: Sales Forecast till 2035 (USD Million)
Table 17.97 Intesti: Sales Forecast till 2035 (USD Million)
Table 17.98 Intesti Bacteriophage: Sales Forecast till 2035 (USD Million)
Table 17.99 Klebsiella Purified Polyvalent Bacteriophage: Sales Forecast till 2035 (USD Million)
Table 17.100 Pyo Bacteriophage: Sales Forecast till 2035 (USD Million)
Table 17.101 SES Bacteriophage: Sales Forecast till 2035 (USD Million)
Table 17.102 Sextaphag®: Sales Forecast till 2035 (USD Million)
Table 17.103 Staphylococcal Bacteriophage: Sales Forecast till 2035 (USD Million)
Table 17.104 Streptococcus Bacteriophage: Sales Forecast till 2035 (USD Million)
Table 17.105 PYO Phage Streptococcus Bacteriophage: Sales Forecast till 2035 (USD Million)
Table 17.106 Unnamed Streptococcus Bacteriophage (Adaptive Phage Therapeutics): Sales Forecast till 2035 (USD Million)

List Of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report:

  1. AB Agri
  2. Adaptive Phage Therapeutics (APT)
  3. AmpliPhi Biosciences
  4. AnimalBiome
  5. Antibacterial Resistance Leadership Group (ARLG)
  6. Aquatic Biologicals
  7. Armata Pharmaceuticals
  8. Assistance Publique - Hôpitaux de Paris (AP-HP)
  9. Balgrist University Hospital
  10. Biomedical Advanced Research and Development Authority
  11. BiomX
  12. BioNTech
  13. C3J Therapeutics
  14. CARB-X
  15. ContraFect
  16. Cornell University
  17. Cystic Fibrosis Foundation
  18. Cytophage Technologies
  19. DuPont Animal Nutrition (now a part of International Flavors & Fragrances (IFF))
  20. Eliava BioPreparations
  21. Eliava Foundation
  22. Eligo Bioscience
  23. EnBiotix (now known as Spexis)
  24. EpiBiome
  25. Felix Biotechnology
  26. FERRING BV
  27. Ferring Pharmaceuticals
  28. Georgia Institute of Technology
  29. GlaxoSmithKline
  30. Hôpital de la Croix Rousse
  31. Hospices Civils de Lyon
  32. IDbyDNA
  33. Hirszfeld Institute of Immunology and Experimental Therapy
  34. Intralytix
  35. Janssen
  36. Johnson & Johnson
  37. JSR
  38. Locus Biosciences
  39. L'Oréal
  40. Maruho
  41. Massachusetts Institute of Technology
  42. Mayo Clinic
  43. Merck
  44. Michael E. DeBakey Veterans Affairs Medical Center
  45. Micreos
  46. Microgen
  47. MicroPhage
  48. National Cancer Institute (NCI)
  49. National Institute of Allergy and Infectious Disease
  50. Navarrabiomed
  51. Oyster Point Pharma
  52. Passport Food Safety Solutions (acquired by Church & Dwight)
  53. Pasteur Institute
  54. Phagelux
  55. PhagePro
  56. PhagoMed
  57. Pherecydes Pharma
  58. Phico Therapeutics
  59. Polyphor
  60. Proteon Pharmaceuticals
  61. Purdue University
  62. Rigshospitalet
  63. RondinX
  64. Sciphage
  65. Sensei Biotherapeutics
  66. Skretting
  67. SNIPR Biome
  68. Southwest Regional Wound Care Center
  69. Stanford University
  70. SyntBioLab
  71. Synthetic Genomics
  72. TechnoPhage
  73. Telum Therapeutics
  74. TFF Pharmaceuticals
  75. The Rockefeller University
  76. The University of Sydney
  77. The Westmead Institute for Medical Research
  78. The Combat Capabilities Development Command Soldier Center (CCDC SC)
  79. United States Department of Defense
  80. United States Department of Veterans Affairs
  81. University Hospital of Montpellier
  82. University of California
  83. University of Pittsburgh
  84. University of Washington
  85. Walter Reed Army Institute of Research (WRAIR)
  86. Yale University

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 8) n a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com